Biotech Values

[skitahoe]

I would suggest you review GNVC once again, a stock I know you've put down in the past. At current prices it's a bargain as without a doubt it will move up nicely on the news of resumption of recruiting patients into cancer trials other then the PACT. They have a broad pipeline, vaccines under development funded by other for Malaria, Foot and Mouth Disease, AIDS, and others. They have a Partnership with Novartis that could bring in over $200M for hearing and balance disorders.

The PACT Trial was a failure, but not because the drug didn't work for Pancreatic Cancer, it does. Patients in the trial who were offered no hope because of not receiving TNFerade remained in the database though they searched out other effective treatment. Abraxane does help pancreatic victim prolong life, but isn't approved yet for that indication, but is approved, so patients looking for benefit turned to it, lengthening the lifespan of many in the SOC group. I know this is speculation as data's not been reported, but it's been clear that the numbers lost to follow up have been high, and these patients are again considered on death. My point is, the trial protocol which permitted this to happen and also clearly permits those receiving the drugs, or not, to clearly know it is flawed, the problem isn't the drug, it's the protocol.

In short, if you didn't like GNVC because of questions about the PACT trial at $3, take a look at it now, at $.70 cents and without the PACT trial. I believe you'll see a reason to make it a long term hold.

Gary